Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SDJ
|
|||
| Drug Name |
Ureido-phenyl-substituted triazine derivative 1
|
|||
| Synonyms |
PMID28270010-Compound-Figure6-1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ABRAXIS BIOSCIENCE, LLC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N8S2
|
|||
| Canonical SMILES |
CC1=CN=C(S1)NC2=NC(=NC(=N2)SC3=CC=C(C=C3)N)N4CCN(CC4)C
|
|||
| InChI |
1S/C18H22N8S2/c1-12-11-20-17(27-12)22-15-21-16(26-9-7-25(2)8-10-26)24-18(23-15)28-14-5-3-13(19)4-6-14/h3-6,11H,7-10,19H2,1-2H3,(H,20,21,22,23,24)
|
|||
| InChIKey |
WLWGUMHFVGHNRD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Endocytosis | ||||
| Apoptosis | ||||
| Neurotrophin signaling pathway | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
| Reactome | Frs2-mediated activation | |||
| ARMS-mediated activation | ||||
| NGF-independant TRKA activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | MAPK Signaling Pathway | |||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.